VENTAVIS Side Effects

7019254-0 | Anaemia, Dyspnoea, Heart Rate Increased, Palpitations
on Sep 08, 2010 Female patient from UNITED STATES , 59 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, dyspnoea, heart rate increased, palpitations. Ventavis dosage: Respiratory. During the same period patient was treated with TRACLEER (125 Mg, Bid, Oral) (View Tracleer Review and Tracleer Label ), REVATIO (View Revatio Review and Revatio Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized.

7008709-0 | Gait Disturbance, Head Injury, Subarachnoid Haemorrhage
Patient was taking Ventavis (View Usage). Patient had the following side effects: gait disturbance, head injury, subarachnoid haemorrhage on Sep 12, 2010 from GERMANY Additional patient health information: Male patient , 50 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: 5 Ug, 6 X Day, Respiratory. During the same period patient was treated with MARCUMAR (View Marcumar Review and Marcumar Label ), TORSEMIDE (View Torsemide Review and Torsemide Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), RANITIDINE HCL (View Ranitidine Hcl Review and Ranitidine Hcl Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ). Patient was hospitalized.

7003946-3 | Colon Cancer, Hepatic Neoplasm Malignant
Adverse event was reported on Sep 03, 2010 by a Male patient taking Ventavis (View Usage) (Dosage: 9 Puffs 4 Times A Day, Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 79 years of age, After Ventavis was administered, patient had the following side effects: colon cancer, hepatic neoplasm malignant. Patient was hospitalized.

6984474-8 | Atrial Pressure Increased, Chest X-ray Abnormal, Circulatory Collapse, Condition Aggravated, Lung Transplant, Oxygen Saturation Decreased, Pulmonary Arterial Pressure, Pulmonary Embolism, Pulmonary Veno-occlusive Disease
on Aug 29, 2010 Female patient from UNITED STATES , 14 years of age, was diagnosed with pulmonary hypertension (What is pulmonary hypertension?) and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: atrial pressure increased, chest x-ray abnormal, circulatory collapse, condition aggravated, lung transplant (What is lung transplant?), oxygen saturation decreased, pulmonary arterial pressure, pulmonary embolism (What is pulmonary embolism?), pulmonary veno-occlusive disease. Ventavis dosage: . During the same period patient was treated with SILDENAFIL CITRATE (View Sildenafil Citrate Review and Sildenafil Citrate Label ), NITRIC OXIDE (View Nitric Oxide Review and Nitric Oxide Label ), OXYGEN (OXYGEN) (View Oxygen (oxygen) Review and Oxygen (oxygen) Label ). Patient was hospitalized.


6981957-1 | Cerebral Haemorrhage
on Aug 31, 2010 Female patient from GERMANY , 67 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient had the following side effects: cerebral haemorrhage. Ventavis dosage: Ug, 8 X Day, Respiratory. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ), VASTAREL (TRIMETAZIDINE HYDROCHLORIDE) (View Vastarel (trimetazidine Hydrochloride) Review and Vastarel (trimetazidine Hydrochloride) Label ), ALDACTAZIDE (View Aldactazide Review and Aldactazide Label ).

6968196-5 | Anaemia, Dyspnoea, Heart Rate Increased, Palpitations
Patient was taking Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: anaemia, dyspnoea, heart rate increased, palpitations on Aug 18, 2010 from UNITED STATES Additional patient health information: Female patient , 59 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: Respiratory. During the same period patient was treated with VANTAVIS (ILOPROST) INHALATION VAPOUR, SOLUTION (View Vantavis (iloprost) Inhalation Vapour, Solution Review and Vantavis (iloprost) Inhalation Vapour, Solution Label ), TRACLEER (Oral) (View Tracleer Review and Tracleer Label ), REVITAIO (SILDENAFIL CITRATE) (View Revitaio (sildenafil Citrate) Review and Revitaio (sildenafil Citrate) Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized.

6967622-5 | Gait Disturbance, Head Injury, Subarachnoid Haemorrhage
Adverse event was reported on Aug 22, 2010 by a Male patient taking Ventavis (View Usage) (Dosage: 5 Ug, 6 X Day, Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: GERMANY , 50 years of age, Patient experienced the following unwanted or unexpected effects: gait disturbance, head injury, subarachnoid haemorrhage. During the same period patient was treated with MARCUMAR (View Marcumar Review and Marcumar Label ), TORSEMIDE (View Torsemide Review and Torsemide Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), RANITIDINE HCL (View Ranitidine Hcl Review and Ranitidine Hcl Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6961077-2 | Cardiac Procedure Complication
on Aug 16, 2010 Female patient from UNITED STATES , 73 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient had the following side effects: cardiac procedure complication. Ventavis dosage: Respiratory. During the same period patient was treated with TADALAFIL (TADALAFIL) (View Tadalafil (tadalafil) Review and Tadalafil (tadalafil) Label ), CALCIUM CHANNEL BLOCKERS (View Calcium Channel Blockers Review and Calcium Channel Blockers Label ). Patient was hospitalized.

6961072-3 |
on Aug 25, 2010 Female patient from UNITED STATES , 48 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). . Ventavis dosage: Respiratory. During the same period patient was treated with REVATIO (View Revatio Review and Revatio Label ).

6942651-6 | Haemoglobin Decreased
Patient was taking Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: haemoglobin decreased on Aug 05, 2010 from UNITED STATES Additional patient health information: Female patient , 77 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: Respiratory. During the same period patient was treated with TRACLEER (View Tracleer Review and Tracleer Label ), CALCIUM CHANNEL BLOCKERS (View Calcium Channel Blockers Review and Calcium Channel Blockers Label ), COUMADIN (View Coumadin Review and Coumadin Label ). Patient was hospitalized.

6923231-5 | Condition Aggravated, Cystic Fibrosis Lung, Off Label Use, Respiratory Failure
Adverse event was reported on Jul 27, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 48 years of age, Patient had the following side effects: condition aggravated, cystic fibrosis lung, off label use, respiratory failure. During the same period patient was treated with VIAGRA (View Viagra Review and Viagra Label ).

6918203-0 | Hepatic Failure, Renal Failure, Sepsis
on Jul 22, 2010 Female patient from UNITED STATES , 70 years of age, weighting 200.0 lb, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: hepatic failure, renal failure, sepsis (What is sepsis?). Ventavis dosage: 6xday, Respiratory, Respiratory. During the same period patient was treated with AMBRISENTAN (AMBRISENTAN) (10 Mg, Qd) (View Ambrisentan (ambrisentan) Review and Ambrisentan (ambrisentan) Label ), REVATIO (View Revatio Review and Revatio Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), RANITIDINE HCL (View Ranitidine Hcl Review and Ranitidine Hcl Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ). Patient was hospitalized.

6918202-9 | International Normalised Ratio Fluctuation
on Jul 22, 2010 Male patient from UNITED STATES , 72 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: international normalised ratio fluctuation. Ventavis dosage: 2.5 ?g, Respiratory. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ).

6917565-8 | Abdominal Pain, Atrial Flutter, Balance Disorder, Constipation, Exercise Tolerance Decreased, Nausea, Right Ventricular Failure, Syncope
Patient was taking Ventavis (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), atrial flutter, balance disorder, constipation (What is constipation?), exercise tolerance decreased, nausea (What is nausea?), right ventricular failure, syncope on Jul 19, 2010 from GERMANY Additional patient health information: Female patient , 75 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: 2.5 Or 5 Ug, 6 X Day, Respiratory. During the same period patient was treated with PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), KONAKION (View Konakion Review and Konakion Label ), NOVALGIN (METAMIZOLE SODIUM) (View Novalgin (metamizole Sodium) Review and Novalgin (metamizole Sodium) Label ), VALORON (TILIDINE HYDROCHLORIDE) (View Valoron (tilidine Hydrochloride) Review and Valoron (tilidine Hydrochloride) Label ). Patient was hospitalized.

6862161-4 | Chest Pain, Oropharyngeal Pain
Adverse event was reported on Jul 05, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: 20 ?g/ml, Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 68 years of age, After Ventavis was administered, patient had the following side effects: chest pain (What is chest pain?), oropharyngeal pain.

6862155-9 | Diarrhoea, Hepatic Enzyme Increased, Renal Failure
on Jul 06, 2010 Female patient from UNITED STATES , 70 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, hepatic enzyme increased, renal failure. Ventavis dosage: Respiratory. During the same period patient was treated with AMBRISENTAN (AMBRISENTAN) (View Ambrisentan (ambrisentan) Review and Ambrisentan (ambrisentan) Label ), REVATIO (View Revatio Review and Revatio Label ). Patient was hospitalized.

6846971-5 | Anal Haemorrhage
on Jun 28, 2010 Female patient from GERMANY , 73 years of age, was diagnosed with pulmonary hypertension (What is pulmonary hypertension?) and was treated with Ventavis (View Usage). Patient had the following side effects: anal haemorrhage. Ventavis dosage: 5 Ug, 3 X Day, Respiratory, Unk Ug, 4 X Day, Respiratory, 2.5 Ug, 3 X Day, Respiratory. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), TORSEMIDE (View Torsemide Review and Torsemide Label ), KALINOR RETARD P (POTASSIUM CHLORIDE) (View Kalinor-retard P (potassium Chloride) Review and Kalinor-retard P (potassium Chloride) Label ), XIPAMID (XIPAMIDE) (View Xipamid (xipamide) Review and Xipamid (xipamide) Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ).

6844964-5 | Glossodynia, Tremor
Patient was taking Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: glossodynia, tremor on Jun 28, 2010 from UNITED STATES Additional patient health information: Male patient , 71 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: 10 Ug, Respiratory. During the same period patient was treated with TRACLEER 9BOSENTAN) TABLET (View Tracleer 9bosentan) Tablet Review and Tracleer 9bosentan) Tablet Label ), REVATIO (View Revatio Review and Revatio Label ), COUMADIN (View Coumadin Review and Coumadin Label ). Patient was hospitalized.

6844881-0 | Hallucination, Headache, Hypotension
Adverse event was reported on Jun 28, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: 10 Ug, Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 67 years of age, Patient experienced the following unwanted or unexpected effects: hallucination, headache (What is headache?), hypotension.

6831692-5 | Ammonia Increased, Encephalopathy, Liver Disorder, Liver Transplant
on Jun 23, 2010 Male patient from UNITED STATES , 56 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient had the following side effects: ammonia increased, encephalopathy, liver disorder, liver transplant (What is liver transplant?). Ventavis dosage: Respiratory. During the same period patient was treated with SILDENAFIL CITRATE (View Sildenafil Citrate Review and Sildenafil Citrate Label ). Patient was hospitalized.

6830735-2 | Atrial Fibrillation, Atrial Flutter, Dyspnoea, Vocal Cord Disorder, Vocal Cord Inflammation
on May 26, 2010 Female patient from UNITED STATES , 52 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), atrial flutter, dyspnoea, vocal cord disorder, vocal cord inflammation. Ventavis dosage: Respiratory. Patient was hospitalized.

6819241-9 | Urinary Tract Infection
Patient was taking Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: urinary tract infection (What is urinary tract infection?) on Jun 16, 2010 from UNITED STATES Additional patient health information: Female patient , 36 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: Oral. During the same period patient was treated with TRACLEER (Oral) (View Tracleer Review and Tracleer Label ), REVATIO (View Revatio Review and Revatio Label ). Patient was hospitalized.

6783249-2 | Nephritis
Adverse event was reported on Jun 03, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: Oral) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 36 years of age, Patient had the following side effects: nephritis. Patient was hospitalized.

6782521-X | Blood Potassium Decreased, Fluid Retention, Renal Disorder, Weight Increased
on Jun 02, 2010 Female patient from GERMANY , 57 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: blood potassium decreased, fluid retention, renal disorder, weight increased. Ventavis dosage: 2.5 Ug, 6x Day, Respiratory. Patient was hospitalized.

6782400-8 | Ammonia Increased, Encephalopathy, Liver Disorder, Transplant
on May 31, 2010 Male patient from UNITED STATES , 56 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: ammonia increased, encephalopathy, liver disorder, transplant. Ventavis dosage: Respiratory. During the same period patient was treated with SILDENAFIL CITRATE (View Sildenafil Citrate Review and Sildenafil Citrate Label ). Patient was hospitalized.

6763462-0 | Cardiogenic Shock, Circulatory Collapse, Convulsion, Hypothermia, Hypoxic Encephalopathy, Loss Of Consciousness, Myocardial Infarction, Pericardial Effusion, Pneumonia Aspiration
Patient was taking Ventavis (View Usage). Patient had the following side effects: cardiogenic shock, circulatory collapse, convulsion, hypothermia (What is hypothermia?), hypoxic encephalopathy, loss of consciousness, myocardial infarction, pericardial effusion, pneumonia aspiration on May 23, 2010 from GERMANY Additional patient health information: Male patient , 54 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: 6 X Day, Respiratory. During the same period patient was treated with TRACLEER (View Tracleer Review and Tracleer Label ), SILDENAFIL CITRATE (View Sildenafil Citrate Review and Sildenafil Citrate Label ), PHENPROCOUMON (PHENPROCOUMON) (View Phenprocoumon (phenprocoumon) Review and Phenprocoumon (phenprocoumon) Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), OXYGEN (OXYGEN) (View Oxygen (oxygen) Review and Oxygen (oxygen) Label ), AMIODARONE (AMIODARONE HYDROCHLORIDE) (View Amiodarone (amiodarone Hydrochloride) Review and Amiodarone (amiodarone Hydrochloride) Label ), MIDAZOLAM HYDROCHLORIDE (View Midazolam Hydrochloride Review and Midazolam Hydrochloride Label ). Patient was hospitalized.

6761506-3 | Anaemia
Adverse event was reported on May 24, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: 5 G, Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 74 years of age, After Ventavis was administered, patient had the following side effects: anaemia. During the same period patient was treated with TRACLEER (125 Mg, Bid, Oral) (View Tracleer Review and Tracleer Label ). Patient was hospitalized.

6759506-2 | Chest Pain, Eye Haemorrhage
on May 18, 2010 Female patient from GERMANY , 59 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), eye haemorrhage. Ventavis dosage: 5 Ug, 6 X Day, Respiratory. During the same period patient was treated with SITAXSENTAN (SITAXENTAN) (View Sitaxsentan (sitaxentan) Review and Sitaxsentan (sitaxentan) Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), TROMCARDIN (ASPARTATE POTASSIUM, MAGNESIUM ASPARTATE) (View Tromcardin (aspartate Potassium, Magnesium Aspartate) Review and Tromcardin (aspartate Potassium, Magnesium Aspartate) Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), MARCUMAR (View Marcumar Review and Marcumar Label ).

6736562-9 | Abdominal Pain Upper, Gastric Dilatation, Nausea
on May 05, 2010 Female patient from GERMANY , 73 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient had the following side effects: abdominal pain upper, gastric dilatation, nausea (What is nausea?). Ventavis dosage: Respiratory.

6725791-6 | Anal Haemorrhage
Patient was taking Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: anal haemorrhage on May 02, 2010 from GERMANY Additional patient health information: Female patient , 73 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: Ug, 4x Day, Respiratory.

6720264-9 | Caesarean Section, Female Sterilisation, High Risk Pregnancy, Oligohydramnios, Tachycardia
Adverse event was reported on Apr 26, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: See Image) was diagnosed with pulmonary arterial hypertension and. Location: PORTUGAL , 21 years of age, Patient experienced the following unwanted or unexpected effects: caesarean section, female sterilisation, high risk pregnancy, oligohydramnios, tachycardia. During the same period patient was treated with OCYTOCIN (OXYTOCIN) (View Ocytocin (oxytocin) Review and Ocytocin (oxytocin) Label ), CALCIUM CHANNEL BLOCKERS (View Calcium Channel Blockers Review and Calcium Channel Blockers Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ). Patient was hospitalized.

6720264-9 | Caesarean Section, Female Sterilisation, High Risk Pregnancy, Oligohydramnios, Tachycardia
on Apr 26, 2010 Female patient from PORTUGAL , 21 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient had the following side effects: caesarean section, female sterilisation, high risk pregnancy, oligohydramnios, tachycardia. Ventavis dosage: See Image. During the same period patient was treated with OXYTOCIN (View Oxytocin Review and Oxytocin Label ), CALCIUM CHANNEL BLOCKERS (View Calcium Channel Blockers Review and Calcium Channel Blockers Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ). Patient was hospitalized.

6720123-1 | Caesarean Section, Oligohydramnios, Premature Baby, Small For Dates Baby
on Apr 26, 2010 Male patient from PORTUGAL , weighting 4.41 lb, was treated with Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: caesarean section, oligohydramnios, premature baby, small for dates baby. Ventavis dosage: Transplacental.

6706733-6 | Acute Right Ventricular Failure, Anxiety, Arteriosclerosis Coronary Artery, Bradypnoea, Cardiac Arrest, Chronic Hepatic Failure, Cyanosis, Delirium, Fall
Patient was taking Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: acute right ventricular failure, anxiety (What is anxiety?), arteriosclerosis coronary artery, bradypnoea, cardiac arrest (What is cardiac arrest?), chronic hepatic failure, cyanosis, delirium, fall (What is fall?) on Apr 12, 2010 from UNITED STATES Additional patient health information: Female patient , 55 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: 5 Ug, Q2hrs, Respiratory, 5 Ug, Q2hrs, Respiratory. During the same period patient was treated with CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), FLOLAN (View Flolan Review and Flolan Label ), REVATIO (View Revatio Review and Revatio Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), CALCIUM W/VITAMIN D (CALCIUM CARBONATE, COLECALCIFEROL) (View Calcium W/vitamin D (calcium Carbonate, Colecalciferol) Review and Calcium W/vitamin D (calcium Carbonate, Colecalciferol) Label ), CELEXA (View Celexa Review and Celexa Label ), COLACE (DOCUSATE SODIUM) (View Colace (docusate Sodium) Review and Colace (docusate Sodium) Label ). Patient was hospitalized.

6692949-4 | Lung Transplant, Off Label Use
Adverse event was reported on Apr 05, 2010 by a Male patient taking Ventavis (View Usage) (Dosage: Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 51 years of age, Patient had the following side effects: lung transplant (What is lung transplant?), off label use.

6689273-2 | Pancreatic Carcinoma
on Apr 06, 2010 Female patient from UNITED STATES , 75 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: pancreatic carcinoma. Ventavis dosage: 5 Ug, Respiratory. During the same period patient was treated with TRACLEER (View Tracleer Review and Tracleer Label ), REVATIO (View Revatio Review and Revatio Label ).

6689272-0 | Ascites, Atrial Fibrillation, Fluid Overload, Hepatic Encephalopathy, Jugular Vein Distension, Oedema, Pneumonia, Right Ventricular Failure, Tachycardia
on Apr 06, 2010 Female patient from UNITED STATES , 74 years of age, weighting 108.0 lb, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, atrial fibrillation (What is atrial fibrillation?), fluid overload, hepatic encephalopathy, jugular vein distension, oedema, pneumonia (What is pneumonia?), right ventricular failure, tachycardia. Ventavis dosage: Respiratory. During the same period patient was treated with SILDENAFIL CITRATE (View Sildenafil Citrate Review and Sildenafil Citrate Label ). Patient was hospitalized.

6686259-9 | Dizziness, Dyspnoea
Patient was taking Ventavis (View Usage). Patient had the following side effects: dizziness (What is dizziness?), dyspnoea on Apr 06, 2010 from UNITED STATES Additional patient health information: Female patient , 54 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: Respiratory.

6678999-2 | Bladder Neoplasm
Adverse event was reported on Apr 02, 2010 by a Male patient taking Ventavis (View Usage) (Dosage: ) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 72 years of age, After Ventavis was administered, patient had the following side effects: bladder neoplasm. Patient was hospitalized.

6666378-3 | Lung Transplant, Off Label Use
on Mar 22, 2010 Male patient from UNITED STATES , 51 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: lung transplant (What is lung transplant?), off label use. Ventavis dosage: Respiratory.

6662412-5 | Pulmonary Hypertension, Right Ventricular Failure
on Mar 16, 2010 Male patient from UNITED STATES , 46 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient had the following side effects: pulmonary hypertension (What is pulmonary hypertension?), right ventricular failure. Ventavis dosage: 5 Ug, Q2h 6xdaily, Respiratory. During the same period patient was treated with REVATIO (View Revatio Review and Revatio Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ).

6656740-7 | Anaemia, Blood Urea Increased, Cardio-respiratory Arrest, Cardiogenic Shock, Hyponatraemia, Pneumonia, Pulmonary Arterial Hypertension, Respiratory Failure, Right Ventricular Failure
Patient was taking Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: anaemia, blood urea increased, cardio-respiratory arrest, cardiogenic shock, hyponatraemia, pneumonia (What is pneumonia?), pulmonary arterial hypertension, respiratory failure, right ventricular failure on Mar 10, 2010 from UNITED STATES Additional patient health information: Female patient , 50 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: Ug, Respiratory. During the same period patient was treated with FLOLAN (Intravenous) (View Flolan Review and Flolan Label ). Patient was hospitalized.

6648629-4 | Adrenal Insufficiency, Condition Aggravated, Disease Progression, Pulmonary Hypertension, Renal Failure
Adverse event was reported on Mar 04, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: 0.250 Mg, Q3hr, Respiratory, 5 Ug, Respiratory) was diagnosed with pulmonary hypertension (What is pulmonary hypertension?) and. Location: GERMANY , 36 years of age, Patient experienced the following unwanted or unexpected effects: adrenal insufficiency, condition aggravated, disease progression, pulmonary hypertension (What is pulmonary hypertension?), renal failure. Patient was hospitalized.

6644565-8 | Blood Pressure Decreased, Brain Natriuretic Peptide Increased, Condition Aggravated, Disease Progression, Gastritis, Liver Function Test Abnormal, Metabolic Acidosis, Nasopharyngitis
on Mar 03, 2010 Female patient from GERMANY , 40 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient had the following side effects: blood pressure decreased, brain natriuretic peptide increased, condition aggravated, disease progression, gastritis, liver function test abnormal, metabolic acidosis, nasopharyngitis. Ventavis dosage: 5 Mcg X 9 Daily, Respiratory. During the same period patient was treated with TRACLEER (View Tracleer Review and Tracleer Label ), REVATIO (View Revatio Review and Revatio Label ), MAGNESIUM (MAGNESIUM) (View Magnesium (magnesium) Review and Magnesium (magnesium) Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), TOREM (TORASEMIDE) (View Torem (torasemide) Review and Torem (torasemide) Label ), MARCUMAR (View Marcumar Review and Marcumar Label ). Patient was hospitalized.

6637798-8 | Anaemia, Cardio-respiratory Arrest, Cardiogenic Shock, Hyponatraemia, Pneumonia, Pulmonary Arterial Hypertension, Right Ventricular Failure, Sinus Tachycardia, Thrombocytopenia
on Feb 26, 2010 Female patient from UNITED STATES , 50 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: anaemia, cardio-respiratory arrest, cardiogenic shock, hyponatraemia, pneumonia (What is pneumonia?), pulmonary arterial hypertension, right ventricular failure, sinus tachycardia, thrombocytopenia. Ventavis dosage: Respiratory. During the same period patient was treated with FLOLAN (Intravenous) (View Flolan Review and Flolan Label ). Patient was hospitalized.

6637768-X | Cardiac Failure, Oedema Peripheral, Pulmonary Oedema
Patient was taking Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure, oedema peripheral, pulmonary oedema on Mar 04, 2010 from UNITED STATES Additional patient health information: Female patient , 70 years of age, weighting 147.7 lb, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: 10 Mcg Solution, Respiratory. During the same period patient was treated with REVATIO (View Revatio Review and Revatio Label ), METOLAZONE (View Metolazone Review and Metolazone Label ), LASIX (View Lasix Review and Lasix Label ).

6633174-2 | Anxiety, Blood Alkaline Phosphatase Increased, Dizziness, Feeling Jittery, Palpitations, Syncope, Tachycardia
Adverse event was reported on Feb 23, 2010 by a Female patient taking Ventavis (View Usage) (Dosage: 5 Ug, 6xday, Respiratory; 2.5 Ug, Single, Respiratory) was diagnosed with pulmonary arterial hypertension and. Location: UNITED STATES , 40 years of age, Patient had the following side effects: anxiety (What is anxiety?), blood alkaline phosphatase increased, dizziness (What is dizziness?), feeling jittery, palpitations, syncope, tachycardia. During the same period patient was treated with REVATIO (View Revatio Review and Revatio Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), OXYGEN (OXYGEN) (View Oxygen (oxygen) Review and Oxygen (oxygen) Label ), DIURETICS (View Diuretics Review and Diuretics Label ). Patient was hospitalized.

6626918-7 | Bronchitis, Dental Caries, Increased Upper Airway Secretion, Postnasal Drip, Stress Urinary Incontinence, Urinary Tract Infection
on Feb 20, 2010 Female patient from UNITED STATES , 80 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). After Ventavis was administered, patient had the following side effects: bronchitis (What is bronchitis?), dental caries, increased upper airway secretion, postnasal drip, stress urinary incontinence, urinary tract infection (What is urinary tract infection?). Ventavis dosage: 5 Ug, Respiratory. During the same period patient was treated with REVATIO (View Revatio Review and Revatio Label ).

6611893-1 | Hospitalisation
on Feb 11, 2010 Male patient from UNITED STATES , 52 years of age, was diagnosed with pulmonary arterial hypertension and was treated with Ventavis (View Usage). Patient experienced the following unwanted or unexpected effects: hospitalisation. Ventavis dosage: 5 Ug, Respiratory. During the same period patient was treated with SILDENAFIL TABLET (View Sildenafil Tablet Review and Sildenafil Tablet Label ), COUMADIN (View Coumadin Review and Coumadin Label ).

6611875-X | Chest Pain
Patient was taking Ventavis (View Usage). Patient had the following side effects: chest pain (What is chest pain?) on Feb 11, 2010 from UNITED STATES Additional patient health information: Male patient , 72 years of age, was diagnosed with pulmonary arterial hypertension and. Ventavis dosage: 5 Ug, 6xdaily, Respiratory; Respiatory. During the same period patient was treated with TRACLEER (125 Mg, Bid, Oral; 62.5 Mg, Bid, Oral) (View Tracleer Review and Tracleer Label ), CALCIUM CHANNEL BLOCKERS (View Calcium Channel Blockers Review and Calcium Channel Blockers Label ). Patient was hospitalized.